Raymond James Financial
SUPN icon

Raymond James Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Raymond James Financial’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.48M Buy
125,293
+36,335
+41% +$1.85M ﹤0.01% 2384
2025
Q4 		$4.42M Buy
+88,958
New +$4.33M ﹤0.01% 2620
2025
Q3 		– Sell
-1,756
Closed -$55.3K – 6564
2025
Q2 		$55.3K Buy
+1,756
New +$56.3K ﹤0.01% 5144
2025
Q1 		– Sell
-189,364
Closed -$6.85M – 4945
2024
Q4 		$6.85M Buy
+189,364
New +$6.67M ﹤0.01% 2113

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's SUPN Position: Q1 2026 in Review

Raymond James Financial increased its Supernus Pharmaceuticals (SUPN) stake by 41% in Q1 2026, buying an estimated $1.85M and bringing the position to 125,293 shares worth $6.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2384.

Raymond James Financial first reported a position in SUPN in Q4 2024 and has held it in 4 quarters since. The position peaked at $6.85M in Q4 2024. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Raymond James Financial held 125,293 shares of Supernus Pharmaceuticals worth $6.48M as of Q1 2026.
  • Raymond James Financial bought 36,335 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.85M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2384 holding.
  • Raymond James Financial first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Raymond James Financial's Supernus Pharmaceuticals position peaked at $6.85M in Q4 2024.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.